3rd Circ. Rejects Novo Nordisk's Medicare Pricing Challenge
By Dan McKay · October 6, 2025, 5:00 PM EDT
The Third Circuit on Monday shot down another challenge to the Medicare drug price negotiation program, denying claims by pharmaceutical giant Novo Nordisk that Congress illegally delegated too much authority to...
To view the full article, register now.